Healthcare and Skincare Sales Decline Due to Delays in New Product Launches
First written in FY2017. 3 of 7 entries say "Worsened", first in FY2018-Q3. Latest entry: FY2021-Q1.
Coca-Cola Bottlers Japan Holdings moved to the "Worse" side of this theme in 2018, 4 years before the typical company in this theme (2022).
The whole theme swung hardest in 2022: 2 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Dropped".
- FY2021-Q1DroppedAnnual report
「The company now has only the continuing beverage business, and the transfer of all shares in キューサイ has been completed.」
The business exposed to the risk of delays in launching new healthcare and skincare products was transferred and excluded from continuing operations. - FY2019-Q2RestatedAnnual report
「Revenue in the healthcare and skincare business was ¥12,306 million, down ¥2,369 million, or 16.1%, year on year, due mainly to the continued decline in sales through its core direct-to-consumer channel.」
Sales through the core direct-to-consumer channel continued to decline, resulting in a 16.1% year-on-year decrease in first-half revenue. - FY2019-Q1WorsenedAnnual report
「Revenue in the healthcare and skincare business was ¥5,966 million, down ¥1,537 million, or 20.5%, year on year, due mainly to declining sales to existing customers, particularly through the direct-to-consumer channel.」
Revenue in the healthcare and skincare business declined 20.5% year on year in the first quarter due to declining sales to existing customers, mainly through the direct-to-consumer channel. - FY2018WorsenedAnnual report
「In the healthcare and skincare business, revenue was ¥27,444 million, down ¥2,460 million, or 8%, from the previous fiscal year, as existing products remained sluggish due to intensifying competition and other factors, despite contributions from new products.」
Despite contributions from new products, weakness in existing products due to intensifying competition continued, and revenue in the healthcare and skincare business fell 8%. - FY2018-Q3WorsenedAnnual report
「In the healthcare and skincare business, revenue was ¥21,153 million, down ¥1,097 million, or 5%, year on year, as existing products remained sluggish due to intensifying competition and other factors, despite contributions from new products.」
Despite contributions from new products, weak sales of existing products due to intensifying competition and other factors contributed to the decline in revenue, which fell 5% year on year. The filing identifies a factor different from the review of television commercial airtime cited for the first half of 2018. - FY2018-Q2Changes in the factors behind the decline in salesAnnual report
「In the healthcare and skincare business, revenue was ¥14,440 million, down ¥579 million, or 4%, year on year, despite contributions from new products, mainly due to the impact of reviewing television commercial airtime and other factors.」
Revenue declined 4% year on year despite contributions from new products, due mainly to the review of television commercial airtime and other factors. The filing identifies a factor behind the decline in sales different from the delay in launching new products cited for the previous period. - FY2017MaterialisedAnnual report
「In the healthcare and skincare business, revenue declined by ¥2,324 million from the previous consolidated fiscal year to ¥29,737 million, down 7.2% year on year, due mainly to delays in launching new products.」
Revenue in the healthcare and skincare business declined 7.2% year on year due to delays in launching new products and other factors.